Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT06109272
Title A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC) (LIVIGNO-2)
Acronym LIVIGNO-2
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AbbVie
Age Groups: adult | senior
Covered Countries USA | FRA | ESP

No variant requirements are available.